MMRGlobal, Inc. (fka MMRF)

[Tulaz1]

March 31, 2011 Conference Call Summary

I am pleased to say MMR is delivering according to our comprehensive business plan.

Revenues and Sales are up in all categories.

We continue to expand our presence on a global basis and we continue to exploit all of our assets including the biotechnology.

As doctors, hospitals, and other medical facilities face mandatory implementation of electronic health records over the course of the next 3 years they are increasingly turning their attention to the technologies that will best meet with their needs and generally serve their office and patients. MMR has the only agnostic advanced way to streamline the transition of communicating electronic medical information with the patient + MMR is the only company that we believe offers a stimulus plan that in actuality could be more lucrative to physicians or healthcare providers than that which is provided by the government.

We are actively pursuing relationships with telecommunication companies to add in medical records as an add-in to the wireless arena. We see that as being a very significant part of our business over the next 12-18 months. We are exploring the use of our equity with a number of strategic partners and we are leveraging our technology to work with those partners and enable us to integrate our products and services with companies that are in the health information and technology space that have products and services that do not compete directly with ours and can be enhanced or improved with the addition of all of our products or a portion of our products.

http://phx.corporate-ir.net/phoenix.zhtml?c=178404&p=irol-newsArticle&ID=1544875&highlight=

2010 was our first full year demonstrating that we can continue to hit consistent singles and advance our position in the marketplace and also confirm that this is a company that is on a trend of creating business milestones.

2010 was a year of consistent singles. There is no such thing as hope. Realistically, we should be able to turn singles into doubles, and triples into grand slams as we continue in 2011.

Questions

China/Unis Updates

China is going well, but slow. China is very time consuming. We must complete the formation of a joint venture before we can receive revenues. There is a tremendous amount of documentation going back and forth and the forms need to be presented where it meets the criteria of translation. We believe over the past several weeks we have completed that process and now there is a requirement by the Chinese govm’t to actually value the intellectual property we are contributing to the venture vs. the intellectual property UNIS contributes so we can formally operate within the joint venture. In the meantime, there have been several RFQ’s that have been responded to by UNIS working with MMR. We have actually engaged the assistance in some of those activities of Alcatel Lucent and we are encouraged by the response of our products and services by various Chinese govm’t officials on both the local level and a national level and as well as on the private hospital level. Additionally we think there is opportunities that were not anticipated when we first signed the agreement with UNIS. It may be more beneficial to us to us to work on a completely separate track with Kodak to sell MMR Pro in that market to private hospitals and smaller clinics. In summary, China is going but going slow, but we are very optimistic about it and the feedback we are getting from the people who we are presenting to is that we keep moving up the ring and stay in the game. We have not made any presentations t anyone in China where we haven’t either qualified to get to the next level or are still in the process of making those presentations. However, no formal agreements would be signed to provide services until the JV is formally established. In China the horizon is similar to the US only it started later. It took a long time to get Hitech legislation to where it is today with forms and goals culminating in 2014. That has not happened yet in China, but we are on the early stage of the curve and I think we will be able to take advantage of every possibility we could have ever anticipated there.

Financial Institution Update

We have signed a comprehensive agreement with one of the largest financial institutions in the world. I can’t mention the name b/c of the confidentiality provisions in the agreement, but it is a lower letter in the alphabet. What we will be doing is creating a safe deposit box using our Esafe platform which will enable the bank to exchange loan documents with consumers in a secure manner in order to speed up the processing of refinancings for real estate with the idea that once the documents are completed they will be left in the Esafe account and the individual will have the opportunity to pay a certain amount of money every single month to be added to their loan processing statement to keep the service. Whether they keep the service or not, the bank will pay us an amount of money that is less than the out of pocket cost they would spend to exchange these documents by courier using FedEx or other commercial services on multiple basis to complete the transaction. We have been working on this project for 3 ½ years and it took forever to design the workflow with this bank for th to go through and do the security audits which were done in both LA and Omaha and Kansas City and recently as I would say 3 months ago we signed the definitive agreement on how that product will work and I am hopeful that we will be able to announce beta testing this year.

Verizon Update

I have had a relationship w/Verizon that goes all the way back to Airtouch. That’s close to 30 years. I have spent a lot of time talking to them recently about why PHR’s should be a significant part of their product offering. I believe we are getting closer to a possible MMR oferring toVerizon customers although there is no definitive agreement at this time. I have focused on the handsets rather than app that can be downloaded, because I think if we can get the real estate in the handsets where we are actually an embedded feature that long term it will be most beneficial to the shareholders. Those things take time but I do no not want to suggest things on this call other than the fact that I feel real good about it.

Institutional Investor Roadshows Update

It is very difficult to find Institutional Investors that are enthusiastically interested in investing in companies that have a market cap and a share price that we are experiencing for the last several months. We had a lot of enthusiasm when the stock was moving into the .30 range and the company was valued near the $60-$70M range. At the current levels it’s hard. Having said that I’ve done two road shows – the first was in New York with 45 people for lunch where it was supposed to last 45 minutes and lasted for 2 ½ hours. We then went to Boston and had equally as enthusiastic a crowd. We had 30 people in attendance at a lunch that was supposed to take 1 hour that ended up lasting 2 hours and 15 minutes. When we are in New York we did notice we did trade close to 1.5M shares that day and I do believe that correlates to that luncheon. In Boston we did not see anything that was definitive. We are currently planning on attending a conference for Microsoft in conjunction of the launch of our products on HealthVault sometime towards the end of April. At that time we plan on doing another road show in Chicago. What we found is that the road shows are really expensive and that it is cheaper to do webinars on the telephone or identify conferences that are geared for OTC companies where institutional investors have specific interest on those companies attend. We’re looking at a strategy of attending those conferences and becoming speakers at that conference. However, when it is practical we will also integrate roadshows in places where it makes sense like in Chicago at the end of the month for the Microsoft HealthVault meeting.

Revenue Guidance Update

When I gave revenue guidance at the end of last year it was based on my belief of certain events happening in a certain way. Whether those events were enthusiasm by the bank to move quicker, Chartis to launch on a more accelerated basis, things would happen on the wireless front in a more accelerated period of time. What has happened was that Chartis did what it was supposed to do, but just not as fast as we would have wanted, but you will see revenue in the 4th Q from Chartis and we have added 250K+ policyholders which have become members of the MMR personal health record network from Chartis. We would have liked to see millions, but we will move towards that number. I unfortunately cannot control the pace at which these companies launch our products and services. I would have thought the bank would have been done by last year. In fact we were told that the launch of the banking service that I talked about would have been done by last year. I believe it will be done this year, but I cannot control how the bank will launch their products and services nor the real estate climate. With MMR Pro we have very successful beta testing. The transition for Kodak for a 520 machine to a 550 scanning machine thinking that it would make the product run faster, easier, better, more streamlined, was greatly appreciated but did not anticipate in that transition we would be going from an off the shelf product to a private label product that would be the subject of a massive purchase agreement. Unfortunately as a result of those activities things take time and things move back. The basis on the numbers that were projected are still facts that I absolutely believe this company can accomplish. What I’ve learned is that I cant control how the other side of the equation (the clients) is going to respond in their timetables vs. our timetables. At this point we have not updated the guidance on a formal basis. The trends are positive, the growth is significant, notwithstanding the fact that some of the biggest items that we thought were going to happen are in the process of happening.

Money from Celgene, When can we expect it?

We started receiving money from Celgene in the 4th Q. A lot of people look at the biotech deal as hope off in to the future in another lifetime. That is not the case. The Celgene transaction and the licensing opportunities that we are looking at have the potential of generating significant amounts of revenues now. Very very soon. The interest in our anti-cd20 products are very very high. The worldwide interest in the research and assets that we have managed to maintain and resurrect from the vaccines trials is significant and we started generating revenues from that and the company should continue to show revenue from that in the 1st Q. I am hoping revenue from those activities will become significant in the near future. I was talking to someone yesterday and I was trying to figure out a way of describing what those assets could mean to our business. It was kind of like when we acquired Favrille somebody either realized and hoped we didn’t find it or didn’t realize and we found it that there was a $300M lottery ticket stuffed in one the back drawers. I’m not suggesting that number for any reason, but that this morning there was a group of people off the east coast that received $300M from a lottery ticket. It’s just coincidental. It is believed that the research and data that is contained in those trials has value of significant amounts. The number we quoted in the 8K with Celgene is a real number and I believe there is a high degree of likelihood we will see those numbers. As a result of that there are other companies, scientists, institutions, and universities around the world that have contacted us and have expressed interest in other aspects of the assets. We have been advised by certain individuals who think that the trial for the vaccine were redesigned that there is a possibility that we could hold assets that could ultimately create a vaccine and that the company may qualify for expedited trials if they wanted to go back and try to launch those vaccines. There are a lot of opportunities. I know associated with those assets are a very very significant amount of tax loss carry forwards and despite the complication of utilization of tax loss carry forwards in todays world I hope this company gets to use every penny of it in my lifetime. Biotech is not based into the valuation of this company and it would be nice if it would be.

Funding for the Company. When will revenues be able to support the company?

The company needs cash to operate in order to execute the kind of business plan that we have. The company needs more cash than we are currently realizing from our revenues. Therefore, we are constantly looking for opportunities either through convertible debt or our equity line to intelligently leverage those financing opportunities for the benefit for the company. At this particular point in time we are relying on the credit line from the RHL Group, the equity line, and the ability to enter into convertible notes. We believe that the convertible notes transaction that we have been able to identify have been at very very favorable terms and we would like to rely on those more than any other financing activity, but because of the tremendous pressure that has been on the stock it makes it difficult to do that. However, I am hoping that over the course of the next few months, you have a picture of the 4th Q, you have a glimpse of what is going on in the 1st Q, we’ve demonstrated that the intellectual property has the ability to generate revenue, and we’ve shown that we have the ability to generate revenue from a variety of sources, not just the majority being MMR Pro. I’m hopeful that the shareholders will rally behind the company as I have, as the board has, and as the vendors have and continue to do. As a result of that it will be easier to finance activities through revenues and some of the convertible notes we have entered into the past.

Revenues Supporting the Company (Ingrid)

We believe we can as fast as our agreements materialize. We have a big pipeline of agreements. Some mover very slow, some move faster than others, and we continue to sign valuable agreements to the company. It is difficult to give a timeline, but there is a very strong pipeline that once all these agreements are working that we should be able to turn the cash flow position in a much better light.
(Bob)
The launch of MMR Pro this year has the ability to bring the company closer to cash flow positive based on revenues, however operations is not the only thing. We have operations, then the expansion into China, constant improvements of our infrastructure, our facilities, and one of the things we are looking at is how are we going to take our platform operations which are very proprietary and deploy them on a worldwide basis. We recognize we will be providing services in China and other parts of the world. People may not want their personal information and medical records stored in Omaha, NE. There are challenges and these challenges require significant contributions towards infrastructure in addition to just operating expenses based on revenues coming into the company. We’ve been very conservative. We are cautious and we need to run this company. We take dilution very seriously. When this company gets diluted – I get diluted the most as the largest shareholder. I think the moves we are making are good. I would encourage everyone to trust the management team.

It shouldn’t be share count that we all worry about. Tell friends and family and get involved in helping the company so it should be more about how big of a truck you will need to load so that you can enjoy the rest of your life in 2011 and 2012.

Possible Acqusitions?

At the time we initiated our strategy to attempt to attempt to rollup the companies in this industry, the market cap of this company was 3-4X higher than it was now and it ade a lot of sense. Today, I would say we are every bit interested in it, however, we need to do it so that it makes financial sense to the shareholders so those are the types of transactions that could have a very dilutive effect if they are not done properly and so we need to identify company’s that can bring significant revenue or we need to identify companies that will deliver value to us in terms of products and services such as a full blown EMR that will enable us to go out and get immediate revenue so that we can increase the share price in a short period of time.